Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA
T cells play a major role in immune defense against viral infections and diseases such as cancer. Accordingly, developing nanoparticle (NP) systems to effectively deliver therapeutics to T cells is of interest. However, NP-mediated delivery of drugs to T cells is challenging because of the nonphagocytic nature of T cells. To engage T cells and induce cellular internalization, NPs are typically decorated with specific receptor-targeting antibodies, often using laborious and costly procedures. Herein, we report that natural glycogen NPs (i.e., nanosugars) with different sizes (20-80 nm) and surface charges (neutral and positively charged) engage Jurkat T cells, undergo intracellular trafficking, and release encapsulated drug without the use of receptor-targeting antibodies. Specifically, glycogen-resveratrol constructs are employed to reactivate HIV-1 latently infected Jurkat T cells (J-Lat A2) and trigger proviral expression. Both neutral and positively charged glycogen NPs engage with J-Lat A2 cells. Large (84 ± 29 nm) and positively charged (23 ± 5 mV) NPs, denoted phytoglycogen-ethylenediamine (PG<sub>EDA</sub>) NPs, readily associate with the cell membrane and are internalized (60%) in J-Lat A2 cells but remain confined in the endocytic vesicles, with moderate reactivation of latent HIV-1 (4.7 ± 0.5%). Conversely, small (21 ± 5 nm) and positively charged (10 ± 6 mV) NPs, bovine glycogen-EDA (BG<sub>EDA</sub>) NPs, associate slowly with T cells but show nearly 100% internalization and efficient endosomal escape properties, resulting in 1.5-fold higher reactivation of latent HIV-1 in T cells. PG<sub>EDA</sub> NPs and BG<sub>EDA</sub> NPs are also internalized by primary human T cells (>90% cell association) and enable the transfection of mRNA, with BG<sub>EDA</sub> NPs showing a 2-fold higher transfection than PG<sub>EDA</sub> NPs. This work highlights the potential of BG<sub>EDA</sub> NPs for the effective intracellular delivery of small-molecule drugs and mRNA in T cells.
Authors
- Darryl N. Johnson (ORCID: https://orcid.org/0000-0003-3205-0371)
- Frank S Caruso (ORCID: https://orcid.org/0000-0002-0197-497X)
- Soraia Fernandes (ORCID: https://orcid.org/0000-0001-7586-1241)
- Marco Cassani (ORCID: https://orcid.org/0000-0001-8437-7734)
- Francesca Cavalieri (ORCID: https://orcid.org/0000-0001-5391-5069)
- Giancarlo Forte (ORCID: https://orcid.org/0000-0002-1341-1023)
- Miriam Quattrociocchi
- Giulio Savazzi
Institutions
- University of Rome Tor Vergata (IT)
- The University of Melbourne (AU)
- King's College London (GB)
- King's College School (GB)
- RMIT University (AU)
Publication Details
- Journal
- ACS Nano
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1021/acsnano.4c09156
- Citations
- 5
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- British Heart Foundation
- RMIT University
- Australian Research Council
- National Health and Medical Research Council
- H2020 Marie Skłodowska-Curie Actions